Clinical characteristics of patients with Anaemia in CKD

APEX study: Prospective Analysis of characteristics of Indian Patients with Anaemia in CKD receiving Wepoxâ?¢ (Human Recombinant Erythropoietin Injection) or Darbotinâ?¢ (r-DNA Origin Erythropoietin Injection) - APEX GO

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/01/030540

Enrollment

5000

Registered

2021-01-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D631- Anemia in chronic kidney disease

Interventions

Intervention1: Wepoxâ?¢ â?? â??Recombinant Human Erythropoietin Injectionâ??: Wepoxâ?¢ â?? â??Recombinant Human Erythropoietin Injectionâ?? 2000IU/ 30000IU/ 4000IU/ 5000IU/10000IU/ 30000IU for Intrave

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients (of age 18-80 years) with Anaemia in CKD prescribed with Wepox• or Darbotin• 2. Patient willing to comply with the study protocol and written informed consent.

Exclusion criteria

Exclusion criteria: 1. Known case of cancer, HIV infection and peri-surgical condition 2. Known case of Pure Red Cell Aplasia (PRCA)

Design outcomes

Primary

Measure	Time frame
Demographic Characteristics Clinical Characteristics Treatment pattern of Wepoxâ?¢ or Darbotinâ?¢ Timepoint: During Visit	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt Ltd.

singole@wockhardt.com022-26596775

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026